Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma): lines of therapy

Cancer page →

2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Early / localised	1
Advanced, first line	1

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Resectable	Distal pancreatectomy with splenectomy (minimally invasive where expertise exists, DIPLOMA), pancreatoduodenectomy for the rare head lesion; adjuvant chemotherapy as for ductal adenocarcinoma when invasive carcinoma is found.	Distal pancreatectomy (removal of the body and tail of the pancreas, usually with the spleen)Robotic & minimally invasive surgeryFOLFIRINOX / mFOLFIRINOXNeoadjuvant / adjuvant / perioperative	NCCN Guidelines: Pancreatic Adenocarcinoma	81

Advanced, first line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Advanced	Treated as pancreatic ductal adenocarcinoma: resection with adjuvant chemotherapy when removable, the chemotherapy rows of the parent page when not; the parent record carries the trials.	FOLFIRINOX / mFOLFIRINOXGemcitabine + nab-paclitaxel	NCCN Guidelines: Pancreatic Adenocarcinoma	81

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.